Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01483274 | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation(AML) | withdrawn | Phase 1 | 0 | University of LouisvilleOTHER | 1 | May 9, 2017 |
| clinicaltrials |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | May 3, 2017 | clinicaltrials |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT01065545 | The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Apr 10, 2015 | clinicaltrials |
| NCT02238522 | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | withdrawn | Phase 1 | 0 | Zenith EpigeneticsINDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT01478074 | ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Altor BioScienceINDUSTRY | 1 | Jan 3, 2014 | clinicaltrials |
| NCT00297921 | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Nov 6, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Dec 2, 2017source: clinicaltrials